Background: Locally advanced laryngeal and hypopharyngeal cancers (LHC) represent a group of cancers for which surgery, laryngectomy-free survival (LFS), overall survival (OS), and progression-free survival (PFS) are clinically meaningful end points.
have only been modestly successful. Advances in chemotherapy and radiation therapy have improved locoregional control and reduced the rate of laryngectomy, while maintaining-but not improving-survival in operable LHC [2, [8] [9] [10] .
Two landmark trials of the Wayne State regimen of cisplatin and fluorouracil (PF) administered for three or four cycles followed by radiotherapy have established this treatment as an alternative to surgical resection in operable LHC [10, 11] . Both trials showed that organ preservation was possible with a minimal effect on survival. More recently, two large phase III trials [Radiation Oncology Therapy Group (RTOG) 91-11 and European Organization for Research and Treatment of Cancer (EORTC) 24954] reported similar results for PF induction and chemoradiotherapy for rates of laryngectomyfree survival (LFS) or functional larynx preservation (FLP) and overall survival (OS) [2, 9] . Furthermore, the RTOG 91-11 study showed that both bolus cisplatin chemoradiotherapy and PF induction chemotherapy significantly improve LFS compared with radiotherapy alone [2, 9] . These trials established PF induction chemotherapy and cisplatin-based chemoradiotherapy as acceptable treatments for avoiding laryngectomy in operable LHC.
Although PF improves survival compared with surgery and/ or radiotherapy in locally advanced head and neck cancer and is considered the standard of care for induction chemotherapy, the addition of docetaxel to cisplatin and fluorouracil (TPF) has further improved outcomes [12] [13] [14] . Two recently completed phase III trials, TAX 324 and EORTC 24971/TAX 323, showed that TPF induction chemotherapy significantly improves survival compared with PF [15, 16] . A third phase III trial in operable LHC [Groupe d'Oncologie Radiotherapie Tête et Cou (GORTEC) 2000-01] demonstrated that TPF significantly improves FLP (defined as being alive without laryngectomy, gastric tube, or tracheostomy) compared with PF [3] . Unlike TAX 323 and GORTEC 2000-01, the TAX 324 trial included patients with tumors who were operable, operable with a low likelihood of cure, or inoperable and studied TPF induction chemotherapy followed by carboplatin-based chemoradiotherapy rather than radiotherapy alone.
In TAX 324, TPF induction chemotherapy followed by chemoradiotherapy reduced the risk of death by 30% [hazard ratio (HR): 0.70; 95% confidence interval (CI): 0.54-0.90; P = 0.006) and the risk of disease progression or death by 29% (HR: 0.71; 95% CI: 0.56-0.90; P = 0.004) compared with PF followed by chemoradiotherapy [15] . Here, we present a subgroup analysis of the patients with LHC from the TAX 324 trial. The aim of this analysis was to compare OS, progression-free survival (PFS), LFS (operable patients), site of treatment failure, and surgery rate between the TPF and PF treatment groups.
patients and methods patients
The TAX 324 trial compared induction chemotherapy with either TPF or PF followed by carboplatin-based chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. A total of 501 patients were randomly assigned to receive either TPF (n = 255) or PF (n = 246) induction chemotherapy. The study design, treatment plan, efficacy, and safety for the entire TAX 324 cohort have been reported previously [15] . All patients with LHC who were included in the original intention-to-treat analysis of the TAX 324 study were included in this subgroup analysis.
Patients with previously untreated, measurable, nonmetastatic, histologically proven stage III or IV squamous cell carcinoma of the oral cavity, larynx, oropharynx, or hypopharynx who were operable (technically resectable) and candidates for organ preservation, operable with a poor chance of cure, or inoperable were eligible. Patients were randomized to receive three cycles of either TPF [docetaxel (Taxotere; Sanofi . Induction chemotherapy was given every 3 weeks for three cycles. Responders in both groups then received 7 weeks of chemoradiotherapy with weekly carboplatin (area under the curve 1.5) and daily radiotherapy, starting 3-8 weeks after the start of the third cycle of induction chemotherapy. Minimum follow-up was 2 years (median 42 months) and 70% of patients had been followed for 3 years at the time of database lock. All data, including those on any surgery occurring after study entry, were extracted from case report forms. A neck dissection after chemoradiotherapy was not considered a treatment failure if it was part of an initial curative treatment of residual or presumptive nodal disease but was included as a surgical procedure in the analysis.
statistical analysis
All primary and regional surgeries after enrollment in the study were documented. The analyses of survival (PFS, LFS, and OS) were conducted on an intention-to-treat basis in the population with LHC. LFS was defined as initially having operable disease, alive, and with no surgery to the primary site. HRs and 95% CIs were obtained using the Cox proportional hazards model. Treatment groups were compared using the log-rank test. Treatment differences on the basis of frequencies were statistically tested using Fisher's exact test. Statistical testing was carried out at a two-sided 0.05 level of significance.
results demographics This subgroup analysis included 166 patients with LHC, of whom 90 received TPF and 76 received PF (Table 1) . Slightly more than half the patients with LHC in the TPF and PF treatment groups had laryngeal cancer (52% and 55%, respectively). Treatment groups were similar with respect to age, performance status, and tumor operability. Although there were more T4 cancers in the TPF group, the comparison between groups was not statistically significant; otherwise the treatment groups were balanced with respect to tumor and nodal status and clinical stage. Overall, 123 patients with LHC (74%) were defined as having operable tumors (TPF, n = 67; PF, n = 56).
survival and disease progression
Treatment with TPF reduced overall mortality by 38% in patients with LHC compared with PF (HR: 0.62; 95% CI: 0.41-0.94, P = 0.024) ( Table 2 ; Figure 1A ). Estimated 3-year survival in patients with LHC was 57% in the TPF group and 40% in original article
Annals of Oncology the PF group. TPF significantly improved PFS, with a 34% reduction in the risk of progression or death compared with PF (HR: 0.66; 95% CI: 0.45-0.97; P = 0.032) ( Table 2 ; Figure 1B ). In a disease site-specific analysis of the 77 patients with hypopharyngeal cancer (TPF, n = 43; PF, n = 34), median OS was 32 months [95% CI: 17 months-not reached (NR)] with TPF versus 20 months (95% CI: 11-46 months) with PF (HR: 0.67; 95% CI: 0.37-1.20; P = 0.18) ( Table 3 ). The estimated 3-year survival for patients with hypopharyngeal cancer receiving TPF was 49% versus 35% for patients receiving PF. The HR for PFS in the hypopharyngeal cancer cohort was 0.76 (95% CI: 0.44-1.32; P = 0.34).
In the 89 patients with laryngeal cancer (TPF, n = 47; PF, n = 42), median OS was 59 months (95% CI: 39-NR) with TPF versus 25 months (95% CI: 13-NR) with PF (HR: 0.58; 95% CI: 0.32-1.04; P = 0.07) ( Table 3 ). The estimated 3-year survival rate for TPF was 65% compared with 45% for PF. In addition, TPF reduced the risk of progression or death in patients with laryngeal cancer by 41% (HR: 0.59; 95% CI: 0.35-1.00; P = 0.05). Survival data for all patients enrolled in TAX 324 and the LHC subgroups are shown in the forest plot in Figure 2 (and supplemental Figures 1 and 2 , available at Annals of Oncology online).
treatment failure and surgery
Although there were fewer total (40% versus 47%), locoregional (32% versus 38%), and distant (6% versus 7%) treatment failures among patients with LHC treated with TPF versus PF, respectively, none of these comparisons reached statistical significance (Table 2) . Likewise, the rates of surgery to the primary tumor site, the neck, or both sites combined were similar between groups, although there was a trend towards fewer primary tumor surgeries in patients receiving TPF versus PF (11% versus 20%; P = 0.19). However, when the number of individuals undergoing any surgery was combined-that is primary site surgery, neck dissection, or both-significantly fewer patients in the TPF group had surgery compared with the PF group (22% versus 42%; P = 0.030).
operable LHC
A total of 123 patients (74%) were defined as having operable LHC, with 67 in the TPF group and 56 in the PF group (Table 4) . Fewer patients in both groups had operable hypopharyngeal cancer compared with the larger LHC population. There was a somewhat greater, but not statistically different, proportion of patients in the TPF group with operable hypopharyngeal cancer compared with the PF group. OS in the two treatment groups was similar, although there was a trend in favor of TPF (HR: 0.67; 95% CI: 0.41-1.11; P = 0.12) (Table 4; Figure 3A) . PFS was significantly better in the TPF group compared with the PF group (HR: 0.61; 95% Annals of Oncology original article CI: 0.40-0.96; P = 0.033) ( Figure 3B ). LFS, which includes components of PFS and OS, was significantly improved with TPF compared with PF (HR: 0.59; 95% CI: 0.37-0.95; P = 0.030), representing a 41% reduction in death or primary site surgery (Table 4 ; Figure 3C ). Importantly, estimated 3-year LFS was 52% versus 32% in the TPF and PF groups, respectively, representing an absolute improvement of 20% in LFS for TPF induction chemotherapy at 3 years.
discussion
TAX 324 was a large phase III trial of sequential therapy comparing induction chemotherapy with either TPF or PF followed by carboplatin-based chemoradiotherapy. The trial showed that TPF improves survival by 30% in patients with locally advanced, operable, and inoperable squamous cell cancer of the oropharynx, larynx, hypopharynx, and oral cavity [15] . The subgroup analysis of patients with LHC presented here demonstrates that TPF improves PFS and OS, reduces the rates of locoregional surgery, and, in operable patients, results in a significant improvement in LFS with a robust absolute improvement of 20% at 3 years compared with PF. Induction chemotherapy has been compared with chemoradiotherapy in two recent trials assessing organ preservation in patients with LHC [2, 9] . In the RTOG 91-11 trial, which studied patients with laryngeal cancer, PF induction chemotherapy followed by radiotherapy alone was similar to chemoradiotherapy with respect to LFS, and both regimens were significantly better than radiotherapy alone [9] . Although the published report of RTOG 91-11 described the primary outcome as laryngeal preservation (defined as not having a laryngectomy), LFS was originally the planned primary end point of the study [17] . Laryngeal preservation rates were significantly higher in the chemoradiotherapy arm compared with the PF arm; however, OS and LFS were similar between the groups because more noncancer deaths occurred in the chemoradiotherapy arm. Survival, locoregional control, and LFS are more relevant clinical and biological end points than laryngeal preservation, as defined in RTOG 91-11. Locoregional control was significantly better in the chemoradiotherapy group compared with PF induction therapy or radiotherapy. However, chemoradiotherapy was associated with an increase in noncancer deaths. This increased mortality in the chemoradiotherapy arm could be considered treatment-related. While survival was similar among all three treatment groups, LFS was similar in the PF induction therapy and chemoradiotherapy arms (44% and original article Annals of Oncology 46%, respectively), and both groups had significantly better LFS compared with radiotherapy alone (32%; P = 0.01 for both comparisons) [9] . In the EORTC 24954 trial in operable LHC, induction PF was again compared with chemoradiotherapy (consisting of alternating PF and radiotherapy) [2] . The primary end point was FLP, defined as being alive, without laryngectomy, gastric tube, or tracheostomy. FLP is a biologically and clinically rational end point that includes global measures of toxicity (tracheostomy, gastric tube) and incorporates OS. This end point was also chosen in the GORTEC 2000-01 trial comparing PF with TPF for laryngeal preservation in operable LHC [3] . The EORTC 24594 trial demonstrated similar rates of FLP and survival for induction PF and chemoradiotherapy. Thus, both EORTC 24954 and RTOG 91-11 demonstrate that induction PF chemotherapy and chemoradiotherapy result in similar rates of either LFS or FLP, as well as survival, in patients with operable disease. In another phase III trial reported by Taylor et al. [18] comparing chemoradiotherapy with induction PF in patients with advanced head and neck cancer, similar rates of survival were reported with PF induction chemotherapy and platinum-based chemoradiotherapy.
We considered comparing LFS in the entire LHC population of TAX 324, but chose to limit the analysis to operable patients in order to more closely represent the populations studied in RTOG 91-11, EORTC 24594, and GORTEC 2000-01 [3] . However, these populations are not directly comparable because TAX 324 included operable patients with more advanced primary tumors and nodal disease than the three organ preservation trials. Nonetheless, there was a significant improvement in LFS and a strong trend for improved survival with TPF induction therapy in patients with LHC, despite the availability of a surgical salvage option. In addition to an improvement in LFS in operable patients, treatment with TPF significantly improved PFS and survival (38% reduction in the risk of death) in the entire LHC population. Although the survival advantage with TPF did not reach statistical significance when the patients with LHC were analyzed separately, it achieved statistical significance for the combined group, which encompasses a patient population with a similar combination of disease sites to patients studied in EORTC 24954 and GORTEC 2000-01. Thus, these results support the Figure 2 . Forest plot showing the risk reduction and 95% confidence intervals (CIs) for overall survival and progression-free survival for the entire TAX 324 cohort, the individual LHC subgroups, and the combined LHC subgroup (intention-to-treat analysis). LHC, laryngeal and hypopharyngeal cancer; PF, cisplatin plus fluorouracil; TPF, docetaxel, cisplatin, plus fluorouracil. [5, 7, 8] . Thus, the improvement in outcomes with TPF induction therapy observed in TAX 324, in which >45% of patients in both treatment groups had advanced hypopharyngeal tumors, is noteworthy. Improved survival in the TPF-treated patients was accompanied by a significant reduction in the rate of surgery. Surgery is an important adjunct to overall therapy, removing residual disease in the neck and salvaging persistent disease at the primary site. Surgery as a salvage approach for primary recurrence or persistence, or for persistent or recurrent adenopathy in the irradiated neck, not only increases survival but also impairs the recovery of functional swallowing. The TAX 324 trial incorporated carboplatin-based chemoradiotherapy as post-induction therapy in all patients. This change in therapeutics, known as sequential therapy, recognizes the high rate of locoregional failure when PF or TPF is followed by radiotherapy alone and was intended to improve survival and locoregional control. Overall, although there was improved survival and a significant reduction in surgery for LHC patients treated with TPF, only a trend for reduced locoregional or distant failures was observed in the TPF group. This analysis should be considered supportive rather than definitive as it represents a post hoc subgroup analysis from a larger trial [15] . However, the large number of patients and the robust statistical outcome lend considerable weight to the results. One example of the problems encountered in structuring this analysis was the identification of the subgroup of patients with operable LHC. The treatment of operable patients and the analysis of studies in this population are different with respect to both intent and outcomes than for patients who have inoperable disease. It would be difficult to propose an end point such as LFS in an inoperable population because such patients would not be comparable to an operable population, neither in the extent or volume of disease nor for the major prognostic indicators of locoregional control and survival. Furthermore, inoperable patients may not have the potential for salvage surgery, unlike operable patients. Hence, for an analysis of LFS, the LHC subgroup was further limited to those patients who had operable tumors in order to make it roughly comparable to the patients entered in RTOG 91-11, GORTEC 2000-01, and EORTC 24954. This is somewhat problematic because the aim of the TAX 324 study was cure and not organ preservation. Therefore, it is likely that many patients, particularly those with technically resectable tumors with low potential for cure, would not have been included in any of the historical organ preservation trials because of the extent of their disease. This may explain the relatively low LFS rate in PF-treated patients reported in this study relative to that reported in the RTOG 91-11 study, despite the use of chemoradiotherapy.
Despite these limitations, this analysis of the TAX 324 LHC subgroup provides confirmatory evidence for the results from GORTEC 2000-01, showing that TPF is superior to PF for organ preservation. Furthermore, the data provide evidence of a substantial and significant advantage in survival and PFS for TPF compared with PF in advanced LHC. All three previously reported phase III trials comparing PF with chemoradiotherapy have shown that PF is equivalent to chemoradiotherapy for organ preservation and survival and superior to surgery and/or radiotherapy [2, 9, 18] . From the results of our subanalysis, and the considerable improvements in LFS and/or survival with TPF compared with PF reported in GORTEC 2000-01, EORTC 24971/TAX 323, and TAX 324, TPF induction therapy, whether followed by radiotherapy or chemoradiotherapy, may well prove to be superior to chemoradiotherapy alone for survival and LFS in LHC. It is reasonable on the basis of multiple studies, therefore, to consider TPF followed by radiotherapy, sequential therapy with TPF and chemoradiotherapy, or chemoradiotherapy each as one of several appropriate therapies for patients with operable or inoperable LHC. Ongoing randomized trials are directly comparing sequential TPF-based therapy with chemoradiotherapy and their results will hopefully further advance our knowledge of the best therapy for patients with LHC [19] . 
